Published in HPB (Oxford) on January 01, 2003
Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg (2007) 1.82
Staging systems in hepatocellular carcinoma. HPB (Oxford) (2005) 1.71
Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford) (2010) 1.59
Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B- or hepatitis C-related hepatocellular carcinoma. Ann Surg (2006) 1.15
The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. BMC Cancer (2013) 1.13
Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma. World J Gastroenterol (2013) 1.02
Level of α-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. Clin Gastroenterol Hepatol (2011) 0.99
Survival analysis of patients with stage I and II hepatocellular carcinoma after a liver transplantation or liver resection. HPB (Oxford) (2014) 0.89
A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma. Hepatology (2015) 0.87
Clinical characteristics of patients with hepatocellular carcinoma in a middle eastern population. Hepat Mon (2013) 0.86
An accurate prognostic staging system for hepatocellular carcinoma patients after curative hepatectomy. Int J Oncol (2014) 0.81
Comparative performances of staging systems for early hepatocellular carcinoma. HPB (Oxford) (2009) 0.81
Tumor size is a major determinant of prognosis of resected stage I hepatocellular carcinoma. Langenbecks Arch Surg (2015) 0.81
Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Impact of Early Response to 4 Weeks of Treatment. Liver Cancer (2015) 0.81
Prediction of Early Recurrence of Liver Cancer by a Novel Discrete Bayes Decision Rule for Personalized Medicine. Biomed Res Int (2016) 0.80
A modified TNM-7 staging system to better predict the survival in patients with hepatocellular carcinoma after hepatectomy. J Cancer Res Clin Oncol (2013) 0.80
Pre-liver transplant biopsy in hepatocellular carcinoma: a potential criterion for exclusion from transplantation? HPB (Oxford) (2012) 0.79
Application of tumor-node-metastasis staging 2002 version in locally advanced hepatocellular carcinoma: is it predictive of surgical outcome? BMC Cancer (2010) 0.79
Morbidity of hepatic resection for intermediate and advanced hepatocellular carcinoma. Langenbecks Arch Surg (2015) 0.78
Multicenter validation study of a prognostic index for portal vein tumor thrombosis in hepatocellular carcinoma. Cancer Res Treat (2014) 0.77
Diagnostic value of cancer-testis antigen mRNA in peripheral blood from hepatocellular carcinoma patients. World J Gastroenterol (2010) 0.76
Reassessing hepatocellular carcinoma staging in a changing patient population. Oncology (2014) 0.76
Comparison of five staging systems in hepatocellular carcinoma treated with sorafenib: A single-center experience. Mol Clin Oncol (2016) 0.75
The best strategy for HCC patients at each BCLC stage: a network meta-analysis of observational studies. Oncotarget (2017) 0.75
Hepatocellular carcinoma surgery outcomes in the developing world: A 20-year retrospective cohort study at the National Cancer Institute of Peru. Heliyon (2016) 0.75
Natural history of hepatocellular carcinoma. Cancer Imaging (2005) 0.75
Simplified HCC-ART score for highly sensitive detection of small-sized and early-stage hepatocellular carcinoma in the widely used Okuda, CLIP, and BCLC staging systems. Int J Clin Oncol (2016) 0.75
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis (1999) 12.31
Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer (1985) 7.67
A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology (1998) 6.47
Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology (1999) 5.64
Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology (2002) 4.83
Simplified staging for hepatocellular carcinoma. J Clin Oncol (2002) 3.48
Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology (2000) 3.30
Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology (2002) 2.68
Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology (2001) 2.10
Purpose of quality standards for infectious diseases. Infectious Diseases Society of America. Clin Infect Dis (1994) 1.70
AJCC/TNM cancer staging, present and future. J Surg Oncol (2001) 1.10
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst (1995) 18.86
Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med (2000) 13.21
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology (1999) 11.76
The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med (2001) 11.48
Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology (2001) 5.80
Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut (2001) 4.12
Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med (2000) 3.97
Evidence for the geographic spread of a methicillin-resistant Staphylococcus aureus clone between Portugal and Spain. J Clin Microbiol (1995) 3.45
Consensus statement on the live organ donor. JAMA (2000) 3.29
Calmodulin target database. J Struct Funct Genomics (2000) 3.20
A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant (2009) 3.09
Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst (1999) 2.98
Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transpl (2001) 2.66
Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut (2000) 2.55
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat (2014) 2.23
Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol (1998) 2.13
Bipap improves survival and rate of pulmonary function decline in patients with ALS. J Neurol Sci (1999) 2.13
The conduct of orthopaedic clinical trials. J Bone Joint Surg Am (1997) 1.96
Mushroom poisoning--from diarrhea to liver transplantation. Am J Gastroenterol (2001) 1.93
Novel mitochondrial DNA deletion found in a renal cell carcinoma. Genes Chromosomes Cancer (1996) 1.81
Screening for hepatocellular carcinoma. Hepatology (1998) 1.78
The importance of hiatal hernia in reflux esophagitis compared with lower esophageal sphincter pressure or smoking. J Clin Gastroenterol (1991) 1.77
Adenocarcinomas arising in tongues or short segments of Barrett's esophagus. Dig Dis Sci (1992) 1.71
Hepatic iron and nonalcoholic fatty liver disease. Hepatology (1999) 1.70
Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat (2014) 1.68
Alphafetoprotein: an obituary. J Hepatol (2001) 1.68
Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat (2014) 1.67
Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res (1996) 1.67
Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut (2002) 1.66
Cardiovascular, renal, and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites. Am J Gastroenterol (1997) 1.61
World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective. J Gastrointestin Liver Dis (2010) 1.52
Deletion in chromosome 11p associated with a hepatitis B integration site in hepatocellular carcinoma. Science (1985) 1.51
Chronic reactive airway disease following acute chlorine gas exposure in an asymptomatic atopic patient. Chest (1991) 1.51
Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects. Arthritis Rheum (1990) 1.50
Fecal occult blood screening for colorectal cancer in a Veterans Administration Hospital. Am J Surg (1983) 1.47
Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: A site-directed mutagenesis study. Environ Health Perspect (1998) 1.46
Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3. J Viral Hepat (2008) 1.45
Delta and conjugated bilirubin as complementary markers of early rejection in liver-transplant recipients. Clin Chem (1990) 1.44
Hostility predicts restenosis after percutaneous transluminal coronary angioplasty. Mayo Clin Proc (1996) 1.42
Rapid degradation of an abnormal protein in Escherichia coli involves the chaperones GroEL and GroES. J Biol Chem (1994) 1.41
Alpha-fetoprotein in antenatal diagnosis of congenital nephrosis. Lancet (1975) 1.34
Trigger factor is involved in GroEL-dependent protein degradation in Escherichia coli and promotes binding of GroEL to unfolded proteins. EMBO J (1995) 1.34
Treatment of primary liver graft nonfunction with prostaglandin E1. Transplantation (1989) 1.34
16, 16 Dimethyl prostaglandin E2 prevents the development of fulminant hepatitis and blocks the induction of monocyte/macrophage procoagulant activity after murine hepatitis virus strain 3 infection. J Clin Invest (1987) 1.33
Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology (2001) 1.32
Correlation of inflammatory infiltrate with the enlargement of experimental aortic aneurysms. J Vasc Surg (1992) 1.29
Barrett's oesophagus and colonic tumours. Lancet (1985) 1.28
Failed primary management of iatrogenic biliary injury: incidence and significance of concomitant hepatic arterial disruption. Surgery (2001) 1.26
Laparoscopic-assisted right lobe donor hepatectomy. Am J Transplant (2006) 1.25
Genome-scale phylogeny of the alphavirus genus suggests a marine origin. J Virol (2011) 1.23
Spontaneous regression of hepatic pseudotumor. Am J Gastroenterol (1992) 1.17
Posttranscriptional stabilization of c-fms mRNA by a labile protein during human monocytic differentiation. Mol Cell Biol (1989) 1.16
Is there a link between cervical inlet patch and Barrett's esophagus? Gastrointest Endosc (2001) 1.15
Biochemical and clinical response of fulminant viral hepatitis to administration of prostaglandin E. A preliminary report. J Clin Invest (1989) 1.15
Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann Intern Med (1995) 1.14
PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer (2012) 1.13
c-myc amplification in hepatocellular carcinoma predicts unfavorable prognosis. Mod Pathol (1996) 1.13
Trigger factor associates with GroEL in vivo and promotes its binding to certain polypeptides. J Biol Chem (1997) 1.13
Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res (2001) 1.09
Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program. Am J Public Health (1998) 1.08
Synaptophysin: a novel marker for neurons, certain neuroendocrine cells, and their neoplasms. Hum Pathol (1986) 1.07
Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. Aliment Pharmacol Ther (2006) 1.07
Therapeutic index of nutritional depletion in hospitalized patients. Surg Gynecol Obstet (1975) 1.06
Serendipitous adrenal masses: prevalence, significance, and management. Am J Surg (1985) 1.06
Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver (2001) 1.05
Liver disease activity and hepatitis B virus replication in chronic delta antigen-positive hepatitis B virus carriers. Hepatology (1985) 1.05
Rapid degradation of an abnormal protein in Escherichia coli proceeds through repeated cycles of association with GroEL. J Biol Chem (1999) 1.05
Pseudomyxoma peritonei associated with colloid carcinoma of the pancreas. Gastroenterology (1986) 1.05
An immunohistochemical study of benign clear cell ('sugar') tumor of the lung. Arch Pathol Lab Med (1991) 1.05
Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl (2001) 1.05
A survey of CMV prevention strategies after liver transplantation. Am J Transplant (2007) 1.03
Inflammatory aspects of experimental aneurysms. Effect of methylprednisolone and cyclosporine. Ann N Y Acad Sci (1996) 1.02
Effects of sex hormones on mesangial cell proliferation and collagen synthesis. Kidney Int (1996) 1.00
Prevalence of oesophagitis in asthmatics. Gut (1992) 1.00
The role of granulomatous phlebitis and thrombosis in the pathogenesis of cirrhosis and portal hypertension in sarcoidosis. Hepatology (1997) 1.00
Neuropathy accompanying IgM lambda monoclonal gammopathy. Acta Neuropathol (1983) 1.00
Atrial infarction: diagnosis and management. Am Heart J (1988) 0.99
Allopurinol-induced granulomatous hepatitis with cholangitis and a sarcoid-like reaction. Arch Intern Med (1978) 0.99
Neuroendocrine carcinomas of the gastrointestinal tract. Semin Diagn Pathol (1984) 0.99
Transarterial chemoembolisation for advanced hepatocellular carcinoma: results from a North American cancer centre. Clin Oncol (R Coll Radiol) (2006) 0.98
Clinical features of duodenal somatostatinomas. Surgery (1993) 0.98
One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. J Clin Oncol (1993) 0.97
Downregulation of c-fms gene expression in human monocytes treated with phorbol esters and colony-stimulating factor 1. Blood (1989) 0.97
Molecular basis for the constitutive activity of estrogen-related receptor alpha-1. J Biol Chem (2001) 0.97
Group B streptococcal lung infection in neonatal rabbits. Pediatr Res (1982) 0.97
Spatial associations among density of cattle, abundance of wild canids, and seroprevalence to Neospora caninum in a population of beef calves. J Am Vet Med Assoc (2000) 0.97
Can topical mitomycin prevent laryngotracheal stenosis? Laryngoscope (1999) 0.96
Gastric parietal cell carcinoma--a newly recognized entity: light microscopic and ultrastructural features. Histopathology (1984) 0.96
Primary nodal gastrinomas. Arch Pathol Lab Med (2000) 0.96
Laparoscopic live donor nephrectomy--is it safe? Transplantation (2000) 0.95
Node-positive duodenal carcinoma is curable. Arch Surg (1997) 0.95
Y chromosome loss in esophageal carcinoma: an in situ hybridization study. Genes Chromosomes Cancer (1993) 0.95
Neuroendocrine carcinomas of the colon. Ultrastructural and biochemical evidence of their secretory function. Am J Surg Pathol (1978) 0.95
Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. Ann Intern Med (1990) 0.94
Outcome of de novo hepatitis C virus infection in heart transplant recipients. Hepatology (1999) 0.94
Acyclovir triphosphate inhibits the diagnostic polymerase chain reaction for cytomegalovirus. Transplantation (1996) 0.94
Some permutation tests for survival data. Biometrics (1996) 0.93
Penetration and metabolism of DDT in resistant and susceptible house flies and the effect on latent toxicity. J Econ Entomol (1966) 0.93
A new system for catheter ablation of atrial fibrillation. Am J Cardiol (1999) 0.93